{"id":"W4402560067","doi":"10.1016/j.annonc.2024.08.681","title":"614MO Type II RAF inhibitor tovorafenib in recurrent/refractory (R/R) melanoma or other solid tumors with RAF fusions and/or RAF1 amplification","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Refractory (planetary science); Cancer research; Melanoma; Solid tumor; Oncology; Internal medicine; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002113609,0.000266932,0.0004998787,0.0001892204,0.0002010709,0.0003343927,0.0002359582,0.0002617126,0.002099817],"category_scores_gemma":[0.0002072336,0.0001029181,0.0003394071,0.0001245127,0.0001060422,0.000205296,0.000143063,0.0006106997,0.0003187298],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000411449,"about_ca_system_score_gemma":0.0004056993,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008328846,"about_ca_topic_score_gemma":0.00388724,"domain_scores_codex":[0.99993,0.00001503513,0.000005749201,0.000007631461,0.000009544687,0.00003203297],"domain_scores_gemma":[0.9999405,0.000008424594,0.000008719052,0.000004845946,0.000004482606,0.00003300552],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1179028,0.005318012,0.02757099,0.001077765,0.001203104,0.005906815,0.0003361808,0.004326199,0.3050991,0.001920764,0.0177338,0.5116044],"study_design_scores_gemma":[0.06211088,0.1807091,0.264754,0.0003453543,0.00249293,0.03493149,0.0008513588,0.02838238,0.2615752,0.002755202,0.1608677,0.0002243066],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9890116,0.005139774,0.0003535539,0.0004585858,0.0001764336,0.00007216797,0.0002369105,0.00009517836,0.004455765],"genre_scores_gemma":[0.9962005,0.001031179,0.0002669894,0.0000967966,0.00002739998,0.0000266663,0.0002743267,0.000007588857,0.002068501],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002099817,"threshold_uncertainty_score":0.007024586,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06356548457946962,"score_gpt":0.3571273992258349,"score_spread":0.2935619146463653,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}